Source: Basic & Clinical Pharmacology & Toxicology. Unidade: FMRP
Subjects: DISPOSITIVOS ANTICONCEPCIONAIS FEMININOS, SÍNDROME DO OVÁRIO POLICÍSTICO (TRATAMENTO), METALOPROTEINASES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOMES, Valéria A. et al. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome. Basic & Clinical Pharmacology & Toxicology, v. 111, n. 3, p. 211-216, 2012Tradução . . Disponível em: https://doi.org/10.1111/j.1742-7843.2012.00895.x. Acesso em: 05 fev. 2025.APA
Gomes, V. A., Vieira, C. S., Jacob-Ferreira, A. L., Belo, V. A., Soares, G. M., França, J. B., et al. (2012). Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome. Basic & Clinical Pharmacology & Toxicology, 111( 3), 211-216. doi:10.1111/j.1742-7843.2012.00895.xNLM
Gomes VA, Vieira CS, Jacob-Ferreira AL, Belo VA, Soares GM, França JB, Ferriani RA, Tanus-Santos JE. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome [Internet]. Basic & Clinical Pharmacology & Toxicology. 2012 ; 111( 3): 211-216.[citado 2025 fev. 05 ] Available from: https://doi.org/10.1111/j.1742-7843.2012.00895.xVancouver
Gomes VA, Vieira CS, Jacob-Ferreira AL, Belo VA, Soares GM, França JB, Ferriani RA, Tanus-Santos JE. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome [Internet]. Basic & Clinical Pharmacology & Toxicology. 2012 ; 111( 3): 211-216.[citado 2025 fev. 05 ] Available from: https://doi.org/10.1111/j.1742-7843.2012.00895.x
